HCPCS Code J7189: Factor VIIa recombinant billing guide

Key takeaways

HCPCS Code J7189 covers Factor VIIa (antihemophilic factor, recombinant), the code for NovoSeven RT, billed per 1 microgram.

Units equal the total micrograms administered, so a 1.2 mg dose is billed as 1,200 units rather than 1.2.

Medicare Part B pays J7189 at ASP plus 6% for FDA-approved indications, and commercial payers usually require prior authorization.

Claims management software like Pabau ties the code, the units, and the diagnosis code together before the claim goes out.

HCPCS Code J7189 covers Factor VIIa (antihemophilic factor, recombinant), billed per 1 microgram administered. The drug billed under it is NovoSeven RT (eptacog alfa activated), manufactured by Novo Nordisk.

It is a Level II J-code maintained by the Centers for Medicare and Medicaid Services (CMS) for physician-administered drugs.

The units field is where these claims fail. Every microgram administered counts as one unit, so a dose reported in milligrams lands 1,000 times short. Mapping the dose to the right unit count in claims management software before submission stops that error at the source.

J7189 code details at a glance

The table below summarizes the core attributes of J7189 for the 2026 billing year.

What drug does J7189 represent?

NovoSeven RT (eptacog alfa activated) is a recombinant form of coagulation Factor VIIa. It works by directly activating the extrinsic coagulation pathway, bypassing the need for Factor VIII or Factor IX. This makes it useful specifically in patients whose hemophilia inhibitors block those clotting factors.

The FDA has approved NovoSeven RT for four indications. Billing claims must pair HCPCS Code J7189 with a diagnosis code that reflects one of these approved uses:

• Hemophilia A or B with inhibitors to Factor VIII or Factor IX
• Acquired hemophilia (inhibitors in patients without a prior hemophilia diagnosis)
• Congenital Factor VII deficiency
• Glanzmann thrombasthenia with refractoriness or contraindication to platelet transfusions

Off-label uses of NovoSeven RT are generally not reimbursable under Medicare or most commercial plans. Claims submitted for non-approved indications will deny. Supporting documentation must clearly establish one of the four approved indications above.

How to calculate units for J7189

One billing unit equals one microgram administered. What trips billers is the milligram-to-microgram conversion that happens before the math. NovoSeven RT vials are labeled in milligrams, while the HCPCS descriptor is written in micrograms.

Conversion formula: milligrams x 1,000 = micrograms = units to bill.

Document the exact dose administered in the clinical record before completing the claim. Payers audit J7189 claims for dose plausibility against the patient’s weight and the approved dosing range. Under-billing wastes revenue, and over-billing invites an audit. The billed units must match the administered dose exactly.

Each J-code sets its own unit, so a conversion learned on one drug does not carry across to the next. J2941 and J1438 are both measured in milligrams, which leaves J7189 as the outlier on most specialty drug claims.

How to bill J7189: Submission requirements

Most J7189 claims run through the buy-and-bill model. The practice acquires NovoSeven RT directly from the manufacturer or distributor, administers it, and then bills the payer for both the drug and administration.

Specialty pharmacy billing (where the pharmacy supplies the drug and bills separately) is less common for this product but exists for some commercial plans.

Buy-and-bill workflow for NovoSeven RT

1. Acquire the drug. Order NovoSeven RT through a specialty distributor. Retain the invoice with the NDC, lot number, and quantity received.
2. Verify prior authorization. Confirm authorization status before administering, as covered in the prior authorization section below. Document the authorization number.
3. Administer and document. Record the exact dose in milligrams in the clinical note, the patient’s weight, the indication, and the route and time of administration.
4. Convert to billing units. Multiply administered milligrams by 1,000 to get micrograms. That figure is the unit count for the claim.
5. Build the claim. Use HCPCS Code J7189 with the calculated units. Attach the appropriate ICD-10-CM diagnosis code. Include the NDC if required by the payer (some MACs and commercial plans mandate it).
6. Submit. File on a CMS-1500 for professional claims or a UB-04 for outpatient hospital/infusion center claims. Use the correct place of service code for the administration setting.

Submitting through a structured clean claim workflow reduces J7189 denials significantly. Every step above earns its place by removing one denial reason, as the sequence below sets out.

Place of service and bill type codes

The place of service code has to match where the drug was actually administered. Hospital outpatient departments and infusion centers bill on a UB-04, while a physician office bills on a CMS-1500.

Medicare coverage for J7189

Medicare Part B covers J7189 when the drug is physician-administered and medically necessary. CMS Billing and Coding Article A56482 governs hemophilia factor products under Medicare.

Coverage is limited to FDA-approved indications and requires documentation supporting the medical necessity of recombinant Factor VIIa over standard clotting factor replacement.

Key medical necessity criteria for Medicare coverage include:

• Confirmed diagnosis of hemophilia A or B with documented inhibitors to Factor VIII or Factor IX
• Clinical evidence that standard factor replacement therapy is ineffective or contraindicated due to inhibitor titers
• Appropriate documentation of the bleeding episode or surgical prophylaxis need
• Administration in a covered setting by or under direct supervision of a physician

Medicare pays on the average sales price the manufacturer reports each quarter, plus a 6% add-on for acquisition and handling. Rates are refreshed every quarter and vary by MAC locality, so a figure checked in January is already stale by April.

J7189 Medicare fee schedule and reimbursement rates

Medicare reimburses J7189 under the Part B Drug Reimbursement methodology. Payment equals ASP plus 6%, where ASP is the weighted average of all manufacturer sales to non-exempt purchasers minus rebates and discounts. CMS updates the ASP quarterly (January, April, July, October).

Because NovoSeven RT is a high-cost biologic, even small errors in the units field translate to large reimbursement discrepancies. Use the CMS Physician Fee Schedule lookup tool to confirm the current quarter’s payment rate for J7189 before finalizing claims. The ASP file is published on the CMS website and updated each quarter.

For the current payment rate, search J7189 in the AAPC HCPCS code lookup, which reflects current CMS data. Rates differ by MAC jurisdiction and locality, so check the jurisdiction that processes your claims.

Diagnosis codes (ICD-10-CM) used with J7189

Every J7189 claim must include at least one ICD-10-CM diagnosis code that establishes the medical necessity of recombinant Factor VIIa. CMS Billing Article A56482 specifies the covered diagnoses. The table below lists the primary codes. Verify them against the current CMS billing article before submitting, since covered code lists are updated annually.

D66 and D67 have no decimal subdivisions, so the diagnosis code on its own cannot show inhibitor status. Record the inhibitor titer in Bethesda units in the clinical note instead, since that documentation is what supports a bypassing agent. Payers read it alongside the diagnosis code when they assess medical necessity.

Prior authorization requirements for J7189

Authorization requirements for J7189 vary by payer and MAC jurisdiction, so the prior authorization process starts before the drug is ordered. Commercial payers typically require authorization for every NovoSeven RT administration, given what the drug costs. Medicare MAC policies differ. Some require authorization for ongoing therapy but not for emergency bleeding treatment.

Typical documentation required for a J7189 prior authorization request:

• Confirmed hemophilia diagnosis with inhibitor titer levels (Bethesda units)
• Documentation of failed or contraindicated standard factor replacement therapy
• Prescribing physician’s clinical rationale for using a bypassing agent
• Proposed dose, frequency, and treatment duration
• Patient weight (used to verify dose plausibility)

Proactive insurance eligibility verification before ordering the drug reduces the risk of a post-administration PA denial. If a PA is denied, document the denial reason and appeal with clinical evidence supporting the FDA-approved indication. Track the authorization number and expiration date to avoid claims that fall outside the approved window.

Related HCPCS codes for hemophilia clotting factors

J7189 belongs to a family of J-codes covering hemophilia factor replacement products. Using the correct code for the specific product administered is essential. Billing J7189 for a Factor VIII product or vice versa will result in a denial and potentially a fraud allegation. The table below maps the most commonly used codes in this family.

Every code in this family except J7189 is measured in international units. J7189 is the only one billed per microgram, which is why a Factor VIII habit produces the wrong unit count on a Factor VIIa claim. Always verify the administered drug’s NDC against the HCPCS code before submitting.

Common billing errors and how to avoid them

J7189 has a higher-than-average denial rate among specialty drug codes. The unit calculation needs a conversion step that most billing systems do not automate by default. Good denial management starts before the claim is filed. These are the most common errors and how to prevent them:

• Units billed in milligrams instead of micrograms. A 1.2 mg dose billed as 1.2 units instead of 1,200 units will deny for underbilling. Build a mg-to-mcg conversion step into the pre-claim checklist.
• Missing or incorrect ICD-10-CM code. Claims without a covered diagnosis code deny on medical necessity grounds. The diagnosis must match one of the approved indications listed in CMS Article A56482.
• No prior authorization. High-cost biologics like NovoSeven RT routinely require PA from commercial payers. Submitting without a valid authorization number results in a denial that is difficult to appeal retroactively.
• Incorrect place of service code. Billing POS 11 (office) for a drug administered in an outpatient hospital setting creates a billing inconsistency. The POS must reflect where administration actually occurred.
• Missing NDC. Payers that require an NDC on J7189 claims will deny without it. Check the payer-specific requirements before submission and include the 11-digit NDC with the N4 qualifier when required.
• Billing J7189 for a different drug. J7189 is specific to NovoSeven RT (eptacog alfa activated). Using it for a different Factor VIIa product or for a Factor VIII product is incorrect coding.

Tracking these claim denial codes after each remittance allows billing teams to identify patterns and correct systemic errors before they accumulate. A structured denial review cycle, ideally weekly for high-cost drug codes, keeps J7189 claim performance within acceptable bounds.

How Pabau keeps J7189 claims accurate before submission

Manual drug billing relies on billers remembering a conversion factor, an authorization rule, and an NDC format for every specialty drug on the formulary. On a low-volume code like J7189, that memory-dependent approach produces denials at a predictable rate.

Practice management software like Pabau holds the drug code, the administered dose, the unit count, and the diagnosis code on one record. Claims then leave through our Claim.MD integration, so the units documented at the point of care are the units the payer receives. Hematology practices and IV therapy services get the same workflow for every product they administer.

The outcome is fewer first-pass denials and a shorter revenue cycle, because the claim carries what the payer asks for the first time. Practices handling medical billing across many drug codes also keep a traceable record from drug receipt through remittance. That trail is what a HIPAA compliance review asks to see.

Bill specialty drugs without the manual math

Pabau keeps the HCPCS code, the administered dose, the unit count, and the diagnosis code on one record. Specialty drug claims then go out complete the first time.

Book a demo

Conclusion

A J7189 claim is decided before it is submitted. The dose in the note, the unit count on the claim, the diagnosis code, and the authorization number all have to agree. No amount of appeal work repairs a mismatch after the money has been denied.

If you bill this code more than occasionally, the change worth making is structural rather than procedural. Put the milligram-to-microgram conversion inside the billing workflow rather than in a biller’s head. The most expensive error on this code then stops being possible.

Everything else on the claim is documentation you already produce, so the work is in capturing it once rather than chasing it twice. Book a demo to see how Pabau handles specialty drug billing across your practice’s code set.

Continue your research

Billing another injectable drug code? HCPCS code J3365 sets out the descriptor, unit definition, and coverage rules for a different J-code.

Handling a high-cost biologic under Part B? HCPCS code J0885 covers the units and Medicare coverage conditions for an ASP-priced injectable.

Reporting a plasma-derived product? HCPCS code J1562 explains how its units and documentation requirements are set.

Buying and billing an infused drug? HCPCS code J9267 walks through units, documentation, and Medicare coverage for a chemotherapy agent.

Frequently asked questions